含紫杉类方案辅助化疗对Her-2阳性乳腺癌患者生存率的影响(2)
第1页 |
参见附件。
参 考 文 献
[1] Early Breast Cancer Trialists Collaborative Group (EBTCG).Effects of Chemotherapy And Hormonal Therapy For Early Breast Cancer On Recurrence And 15-Year Survival:AnOverview Of The Randomized Trials.Lancet,2005,365(9472):1687-1717.
[2] Winstanley J,Cooke T,Murray GD,et al.The Long Term Prognostic Significance ofCerbB-2 in Primary Breast Cancer.Br J Cancer,1991,63(4):447-450.
[3] Levine MN,Pritchard KI,Bramwell VH,et al.A Randomized Trial Comparing Cyclophosphamide, Epirubicin, Fluorouracil With Cyclophosphamide, Methotrexate, Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trial Group Trial MA5.J Clin Oncol,2005,23(22):5166-5170.
[4] Thor AD,Berry DA,Dudman DR,et al.ErbB-2,P53,and Efficacy of Adjuvant Therapy in Lumph Node-Positive Breast Cancer.J Natl Cancer Inst,1998,90(18):1346-1360.
[5] Henderson IC,Berry DA,Demetri GD,et al.Improved Outcomes From Adding Sequential Paclitaxel but not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer.J Clin Oncol,2003,21(6):976-983.
[6] Konecny GE,Thomssen C,Luck HJ,et al.Her-2/neu Gene Amplification and Respond to Paclitaxel in Patients with Metastatic Breast Cancer.J National Cancer Institute,2004,96(15):1141-1151.
[7] Hayes DF,Thor AD,Dressler LG,et al.Her-2 and Response to Paclitaxel in Node-Positive Breast Cancer.N Engl J Med,2007,357(15):1496-1506.
您现在查看是摘要介绍页,详见PDF附件。